http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20140033522-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_519582e84981b0afa92094297c2cf845 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2006-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dcf2e66d3bc382ea97ddf346626e523 |
| publicationDate | 2014-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20140033522-A |
| titleOfInvention | Pharmaceutical composition containing arsenic acid for treating genitourinary cancer and metastases thereof, sodium salts thereof and derivatives thereof |
| abstract | The present application relates to pharmaceutical compositions and methods for the treatment of human genitourinary diseases and bone metastases, said pharmaceutical compositions comprising an effective amount of an alkali metal or alkaline earth metal salt and / or a pharmaceutically acceptable adjuvant . The alkaline non-acid metal salt of the present invention is sodium meta-nonsate (AsO 2 Na) or potassium meta-nonsate (AsO 2 K). The effective amount of the alkali metal salt or alkali metal arsenic acid salt is preferably from 0.0001 to 1500 mg / unit body weight / day, preferably from 1 to 1000 mg / unit body weight / day, more preferably from 1 to 150 mg / Kg / day, and most preferably 50 to 100 mg / kg body weight / day. Dosage formulations of the pharmaceutical compositions of the present invention may be oral dosage forms such as tablets, capsules, powders and / or solutions containing pharmaceutically acceptable carriers, diluents or excipients. |
| priorityDate | 2005-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 183.